



Stereotaxis' Leadership in Robotic Cardiac Ablation to be Showcased at Heart Rhythm 2017 and First Annual Meeting of Society for Cardiac Robotic Navigation (Americas)

April 25, 2017

ST. LOUIS, April 25, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the annual Heart Rhythm Society (HRS) Scientific Sessions at McCormick Place in Chicago from May 10-13.

With a message centered on the effectiveness of Stereotaxis' robotic technologies to improve patient outcomes and positively transform electrophysiology (EP) practices, the Company will present recent clinical results and case studies, demonstrate and provide hands-on interactions with its Niobe[®] system, and be showcased in the inaugural meeting of the Americas chapter of the Society for Cardiac Robotic Navigation (SCRN[A]). Stereotaxis representatives will be available to discuss strategies for building a successful robotic ablation practice in Exhibit Hall Booth #1555.

On Tuesday prior to the opening of HRS, the SCRN(A) will host a symposium at Advocate Christ Medical Center in Oak Lawn, which will feature a live EP procedure using the Niobe system along with detailed insight into clinical applications and best practices for robotic ablation. SCRN is a society of leading electrophysiologists experienced in and advocating for further adoption of robotic technologies in interventional medicine. The symposium will serve as the SCRN(A)'s first annual meeting, which follows the European chapter's inaugural meeting this past October in Amsterdam. Dr. Eugene Crystal, SCRN(A) President, and Dr. Georg Nöcker, SCRN(EU) Founder, will co-chair the event.

In the HRS Rhythm Theatre on Friday, May 12, Stereotaxis will offer a program highlighting the safe, effective utility of robotics in ablation for a wide variety of cardiac arrhythmias. Chaired by Dr. Dhanunjaya Lakkireddy of The University of Kansas Medical Center, the program will feature case reviews by a panel of expert robotic operators, including Dr. Sabine Ernst of Royal Brompton Hospital (London), Dr. Pasquale Santangeli at the Hospital of the University of Pennsylvania (Philadelphia), Dr. Tamas Szili-Torok of Erasmus Medical Center (Rotterdam, NL) and Dr. J. Peter Weiss at Intermountain Health Care (Murray, UT). In addition, HRS scientific proceedings will include three posters with the latest clinical data related to Stereotaxis technologies.

The Stereotaxis booth space will replicate the experience of a Niobe lab through several computer-based and physical simulations, which offer participants first-hand observation of the ease and effectiveness of robotic solutions in complex ablations. The Company also will demonstrate the latest iteration of the e-Contact[™] module, its automated contact confirmation system designed to improve evaluation of tip-to-tissue contact, and showcase its newest generation Odyssey[®] Vision system.

About Stereotaxis

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis' systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Company Contacts:

David L. Fischel

Chairman and Acting Chief Executive Officer

Martin C. Stammer

Chief Financial Officer

investors@stereotaxis.com



Stereotaxis, Inc.